Mineralys Therapeutics Director AKKARAJU SRINIVAS Buys 588235 Shares at $25.5/Share

Mineralys Therapeutics, Inc. [MLYS] announced that Director AKKARAJU SRINIVAS has acquired 588,235 shares at a price of $25.50 per share on September 4, 2025.

Mineralys Therapeutics, Inc. [MLYS] announced that Director AKKARAJU SRINIVAS has acquired 588,235 shares at a price of $25.50 per share on September 4, 2025. This transaction represents a significant investment in the company, which is currently valued at $2.65 billion. The shares were purchased at a price that is $10.43 below the current trading price of $35.93, indicating a potential undervaluation.

The acquisition comes at a time when Mineralys Therapeutics is experiencing remarkable momentum. In the past week alone, the stock has seen a 132% gain, approaching its 52-week high of $36.73. According to InvestingPro analysis, the company appears overvalued relative to its Fair Value [1].

Following the transaction, RA Capital Healthcare Fund LP directly holds 5,456,521 shares of Mineralys Therapeutics, while RA Capital Nexus Fund III, L.P. holds 1,867,229 shares. The company maintains strong financial health with a current ratio of 15.12, indicating robust liquidity [1].

In other recent news, Mineralys Therapeutics, Inc. reported positive subgroup data from its Phase 3 Launch-HTN trial, showcasing significant blood pressure reductions with its aldosterone synthase inhibitor, lorundrostat. This data was presented at the American Heart Association Hypertension Scientific Sessions and highlighted consistent efficacy across various high-risk subgroups [1].

Additionally, Mineralys Therapeutics has launched a $175 million public stock offering to support the development of lorundrostat, including research and pre-commercialization activities [1].

References:
[1] https://www.investing.com/news/insider-trading-news/ra-capital-healthcare-fund-buys-mineralys-therapeutics-shares-for-30m-93CH-4230336